FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031306557> ?p ?o ?g. }

• W3031306557 endingPage "2013" @default.
• W3031306557 startingPage "2005" @default.
• W3031306557 abstract "Background This study reports the outcomes of a single institutional experience treating non‐small cell lung cancer (NSCLC) involving the pulmonary hilum with low‐dose stereotactic body radiation therapy (SBRT). The authors also present a series of repeat hilar SBRT. Methods Inclusion criteria required treatment with SBRT for NSCLC involving regional lymph nodes of the: (i) hilum, (ii) mediastinum, (iii) aortopulmonary window (station 5), or (iv) mainstem bronchus. At least one clinical follow‐up with imaging was required, unless the patient had a prior documented death from cancer. Results A total of 32 patients with 44 treatments were included, and 37 treatments targeted the hilum directly, with seven concerning the mediastinum, AP window, or mainstem bronchus. Median dose was 28 Gy in four fractions with once‐weekly fractionation. At a median clinical follow‐up of 23 months, local control was 64%. Median overall survival was 24 months, and median progression‐free survival was 15 months. A total of 48% of treatments resulted in complete radiographic response on last imaging follow‐up, and no cases of grade ≥ 3 toxicity were reported. For repeat SBRT (after prior hilar SBRT), local control was 92%. Median overall survival was 20 months, and median progression‐free survival was 19 months. Complete radiographic response was noted after 58% of treatments, with 0 instances of progressive response and no reported side effects. Conclusions Low‐dose hilar SBRT was efficacious and well‐tolerated, with impressive overall survival and no grade ≥ 3 toxicity. Repeat treatments with SBRT were feasible and effective, demonstrating overall survival, local control, and toxicity comparable to primary treatments. Key points Significant findings of the study Low‐dose hilar SBRT was efficacious and well‐tolerated Repeated treatments with SBRT demonstrated encouraging results, comparable to primary treatments What this study adds This study contributes to the small body of literature concerning hilar SBRT Repeat hilar SBRT was safe and feasible Toxicity was minimal with low‐dose SBRT Once‐weekly fractionation may have contributed to low rate of side effects." @default.
• W3031306557 created "2020-06-05" @default.
• W3031306557 creator A5025195325 @default.
• W3031306557 creator A5045756378 @default.
• W3031306557 creator A5052495091 @default.
• W3031306557 creator A5069912292 @default.
• W3031306557 creator A5079329366 @default.
• W3031306557 creator A5085919642 @default.
• W3031306557 date "2020-05-29" @default.
• W3031306557 modified "2023-09-27" @default.
• W3031306557 title "Low‐dose hilar and mediastinal stereotactic body radiation therapy for non‐small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment" @default.
• W3031306557 cites W1525896368 @default.
• W3031306557 cites W1874454018 @default.
• W3031306557 cites W1981905971 @default.
• W3031306557 cites W2016243066 @default.
• W3031306557 cites W2020786970 @default.
• W3031306557 cites W2024121508 @default.
• W3031306557 cites W2039664069 @default.
• W3031306557 cites W2041602527 @default.
• W3031306557 cites W2048229815 @default.
• W3031306557 cites W2049119588 @default.
• W3031306557 cites W2061137918 @default.
• W3031306557 cites W2069787198 @default.
• W3031306557 cites W2071364157 @default.
• W3031306557 cites W2110735504 @default.
• W3031306557 cites W2115646671 @default.
• W3031306557 cites W2119975047 @default.
• W3031306557 cites W2122587572 @default.
• W3031306557 cites W2128366510 @default.
• W3031306557 cites W2136305525 @default.
• W3031306557 cites W2159746573 @default.
• W3031306557 cites W2167925953 @default.
• W3031306557 cites W2179010101 @default.
• W3031306557 cites W2276183129 @default.
• W3031306557 cites W2278059368 @default.
• W3031306557 cites W2295756262 @default.
• W3031306557 cites W2309884927 @default.
• W3031306557 cites W2466033276 @default.
• W3031306557 cites W2532166168 @default.
• W3031306557 cites W2558300230 @default.
• W3031306557 cites W2621684067 @default.
• W3031306557 cites W2757031869 @default.
• W3031306557 cites W2767566123 @default.
• W3031306557 cites W2807552403 @default.
• W3031306557 cites W2883480478 @default.
• W3031306557 cites W2883639123 @default.
• W3031306557 cites W2891347610 @default.
• W3031306557 cites W2896883657 @default.
• W3031306557 cites W2900195904 @default.
• W3031306557 cites W2911419136 @default.
• W3031306557 cites W2926245852 @default.
• W3031306557 cites W2951525209 @default.
• W3031306557 cites W4234236664 @default.
• W3031306557 doi "https://doi.org/10.1111/1759-7714.13501" @default.
• W3031306557 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7327689" @default.
• W3031306557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32469465" @default.
• W3031306557 hasPublicationYear "2020" @default.
• W3031306557 type Work @default.
• W3031306557 sameAs 3031306557 @default.
• W3031306557 citedByCount "2" @default.
• W3031306557 countsByYear W30313065572022 @default.
• W3031306557 countsByYear W30313065572023 @default.
• W3031306557 crossrefType "journal-article" @default.
• W3031306557 hasAuthorship W3031306557A5025195325 @default.
• W3031306557 hasAuthorship W3031306557A5045756378 @default.
• W3031306557 hasAuthorship W3031306557A5052495091 @default.
• W3031306557 hasAuthorship W3031306557A5069912292 @default.
• W3031306557 hasAuthorship W3031306557A5079329366 @default.
• W3031306557 hasAuthorship W3031306557A5085919642 @default.
• W3031306557 hasBestOaLocation W30313065571 @default.
• W3031306557 hasConcept C126322002 @default.
• W3031306557 hasConcept C126838900 @default.
• W3031306557 hasConcept C141071460 @default.
• W3031306557 hasConcept C143998085 @default.
• W3031306557 hasConcept C146357865 @default.
• W3031306557 hasConcept C151730666 @default.
• W3031306557 hasConcept C155806632 @default.
• W3031306557 hasConcept C2776178081 @default.
• W3031306557 hasConcept C2776256026 @default.
• W3031306557 hasConcept C2777714996 @default.
• W3031306557 hasConcept C2779126056 @default.
• W3031306557 hasConcept C2779431647 @default.
• W3031306557 hasConcept C2779819216 @default.
• W3031306557 hasConcept C2780314925 @default.
• W3031306557 hasConcept C2780940725 @default.
• W3031306557 hasConcept C2989005 @default.
• W3031306557 hasConcept C509974204 @default.
• W3031306557 hasConcept C71924100 @default.
• W3031306557 hasConcept C86803240 @default.
• W3031306557 hasConceptScore W3031306557C126322002 @default.
• W3031306557 hasConceptScore W3031306557C126838900 @default.
• W3031306557 hasConceptScore W3031306557C141071460 @default.
• W3031306557 hasConceptScore W3031306557C143998085 @default.
• W3031306557 hasConceptScore W3031306557C146357865 @default.
• W3031306557 hasConceptScore W3031306557C151730666 @default.
• W3031306557 hasConceptScore W3031306557C155806632 @default.
• W3031306557 hasConceptScore W3031306557C2776178081 @default.
• W3031306557 hasConceptScore W3031306557C2776256026 @default.

• next